1. Home
  2. GNLX vs SENS Comparison

GNLX vs SENS Comparison

Compare GNLX & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.90

Market Cap

113.6M

Sector

Health Care

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$6.40

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
SENS
Founded
2001
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
113.6M
301.2M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
GNLX
SENS
Price
$2.90
$6.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$17.25
$18.38
AVG Volume (30 Days)
155.2K
1.2M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
N/A
EPS
N/A
N/A
Revenue
$8,000.00
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$2.29
$0.41
52 Week High
$8.54
$8.75

Technical Indicators

Market Signals
Indicator
GNLX
SENS
Relative Strength Index (RSI) 54.98 56.27
Support Level $2.39 $6.40
Resistance Level $2.97 $6.87
Average True Range (ATR) 0.22 0.47
MACD -0.01 0.11
Stochastic Oscillator 42.33 90.06

Price Performance

Historical Comparison
GNLX
SENS

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: